businessbriefs
11:29in productionCh. 1 · Scale, certified/ 11:29 · ceiling 15 min
Companies · Strategy

Sun Pharma

1983

Sun Pharma proves that global scale in generics isn’t built on patents or pipelines — it’s built on factories, filings, and foot soldiers in FDA, EMA and CDSCO exam rooms.

Sun Pharma is a vertically distributed generic drug manufacturer whose scale is real, verifiable, and geographically dispersed — but whose economics, margins, and strategic vulnerabilities remain undocumented in the source material.

CompaniesStrategyGlobalisationSupply chainsPhotographyGlobalisation across the network →
Chapters & takeaways4
  1. 1:10
    Scale, certified

    Sun Pharma is India’s largest pharma company and the world’s fourth largest specialty generic player — a claim verified by its own documentation.

  2. 3:19
    Global reach, concentrated revenue

    70% of revenue is international, but over 60% of turnover still comes from just two countries: the US and India.

  3. 5:24
    Factories before flags

    43 manufacturing sites across six continents signal operational complexity — not just ambition.

  4. 7:24
    Therapeutic sprawl as infrastructure

    15 therapeutic areas covered means breadth, not depth — a portfolio strategy for regulatory and reimbursement arbitrage.

Worth your time?

Yes. Study the whole thing.

4/ 5
What works
  • geographic revenue split
  • manufacturing footprint
  • therapeutic coverage
  • market position claims
What does not
  • financial performance
  • R&D investment
  • regulatory outcomes
  • pricing power
Study it if
  • investors assessing operational scale
  • policy analysts studying generic market structure
  • competitors benchmarking manufacturing footprint
Skip it if
  • those seeking valuation signals
  • analysts needing margin data
  • journalists investigating corporate conduct
The written brief1 min read

What the company or idea is

Sun Pharma is an Indian multinational pharmaceutical company, founded in 1983 and headquartered in Mumbai. It is the largest pharmaceutical company in India and the fourth largest specialty generic pharmaceutical company in the world.

How it actually makes money

Sun Pharma makes money by manufacturing and selling generic pharmaceutical formulations and active pharmaceutical ingredients (APIs) in over 100 countries. Around 70% of its revenue comes from international markets, with the US and India alone accounting for over 60% of turnover.

What works

Its global manufacturing presence — 43 locations across India, the US, Asia, Africa, Australia and Europe — enables local supply and regulatory alignment. Its product portfolio spans 15 therapeutic areas, including psychiatry, oncology, dermatology and ophthalmology, allowing cross-market leverage.

What does not

The material does not establish how Sun Pharma prices its products, what its margins are, how much it spends on R&D or regulatory compliance, or how it manages supply-chain risk across 43 manufacturing sites. It says nothing about profitability, debt, or shareholder returns.

What to take from it

Scale in generics is defined by manufacturing footprint and therapeutic coverage — not innovation or branding. Sun Pharma’s model rests on volume, regulatory approvals across jurisdictions, and distribution in high-volume markets like the US and India.

Is it worth your time

Yes — if you are assessing how scale, geographic diversification, and therapeutic breadth operate in the global generics business without relying on hype or unverified financial claims.

Same desk · Companies4 of 217
12:57
MeituanWang Xing · 2010Meituan is a Chinese technology company headquartered in Beijing that operates a platform for local services, including on‑demand food delivery, in‑store services, consumer reviews under Dazhong Dianping, hotel and travel bookings, and instant retail. It monetises through fees on its platform, taking a commission on food delivery orders and charging merchants for booking and in‑store services. Meituan’s rapid user growth is driven by its extensive coverage of local services, its integration of food delivery, in‑store services, and hotel bookings creating a one‑stop shop, and its large merchant base of 14.5 million active merchants providing network effects. Meituan faces regulatory scrutiny in China, its 2021 post by Wang Xing triggered a 7.1 % share plunge and anti‑monopoly investigation, and the company has been subject to scrutiny by Beijing Municipal Human Resources and Social Security Bureau. Meituan demonstrates the power of a diversified local‑services platform, its ability to scale across cities and internationally shows the importance of network effects, and its regulatory challenges highlight the need for compliance awareness. Meituan offers a case study in rapid scaling and diversification, but its regulatory risks caution investors.
10:56
ABBCharles Eugene Lancelot Brown · 1988ABB is a post-merger industrial incumbent whose value lies in proven, regulated, physical infrastructure — not software, platforms, or scalability stories.
10:50
AbbVie2012AbbVie is a textbook example of post-innovation pharmaceutical value extraction — built on a single blockbuster, sustained by patent thickets and pricing, checked only by biosimilars and congressional scrutiny.
11:08
Abu Dhabi National Oil Company1971ADNOC is the state-owned oil company of Abu Dhabi, UAE — founded by concession in 1939, ranked 12th globally by production, and expanding output to 5 million barrels per day by 2027. It is the UAE’s largest oil company. Output rose from ~2.5 mbpd in the 1990s to 2.9 mbpd in 2008 and 4.85 mbpd in 2024. It is described as efficient and well managed, but financially opaque. It is one of few oil companies increasing production amid climate pressure.
Up next in Business

Suncor Energy

1917 · 11:11

Suncor isn’t a pioneer—it’s a consolidation play built on one province’s tar sands and two governments’ exits.

Play nextBack to Companies
11:11